Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach

Yukinori Kurokawa, Han Kwang Yang, Haruhiko Cho, Min Hee Ryu, Toru Masuzawa, Sook Ryun Park, Sohei Matsumoto, Hyuk Joon Lee, Hiroshi Honda, Oh Kyoung Kwon, Takashi Ishikawa, Kyung Hee Lee, Kazuhito Nabeshima, Seong Ho Kong, Toshio Shimokawa, Jeong Hwan Yook, Yuichiro Doki, Seock Ah Im, Seiichi Hirota, Seokyung HahnToshirou Nishida, Yoon Koo Kang

    Research output: Contribution to journalArticlepeer-review

    56 Citations (Scopus)


    Background:Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function.Methods:We conducted an Asian multinational phase II study for patients with gastric GISTs ≥10 cm. Patients received neoadjuvant imatinib (400 mg/day) for 6-9 months. The primary end point was R0 resection rate.Results:A total of 56 patients were enroled in this study. In the full analysis set of 53 patients, neoadjuvant imatinib for ≥6 months was completed in 46 patients. Grade 3-4 neutropenia and rash occurred in 8% and 9%, respectively, but there were no treatment-related deaths. The response rate by RECIST was 62% (95% CI, 48-75%). The R0 resection rate was 91% (48/53) (95% CI, 79-97%). Preservation of at least half of the stomach was achieved in 42 of 48 patients with R0 resection. At the median follow-up time of 32 months, 2-year overall and progression-free survival rates were 98% and 89%, respectively.Conclusions:Neoadjuvant imatinib treatment for 6-9 months is a promising treatment for large gastric GISTs, allowing a high R0 resection rate with acceptable toxicity.

    Original languageEnglish
    Pages (from-to)25-32
    Number of pages8
    JournalBritish journal of cancer
    Issue number1
    Publication statusPublished - Jun 27 2017

    All Science Journal Classification (ASJC) codes

    • Oncology
    • Cancer Research


    Dive into the research topics of 'Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach'. Together they form a unique fingerprint.

    Cite this